Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis
This study demonstrates that HIPK2 inhibition weakens oncogenic KRAS activity and pancreatic tumorigenesis providing a rationale for testing HIPK2 inhibitors to mitigate the incidence of PDAC development in high-risk individuals.
Authors
- Cinzia Rinaldo (ORCID: https://orcid.org/0000-0001-6124-762X)
- Silvia Sozzi
- Laura Monteonofrio (ORCID: https://orcid.org/0000-0003-3981-942X)
- Silvia Soddu
- Davide Valente (ORCID: https://orcid.org/0000-0001-6397-3641)
- Armando Bartolazzi (ORCID: https://orcid.org/0000-0001-7820-5127)
- Maria Grazia Diodoro (ORCID: https://orcid.org/0000-0002-8504-8059)
- Isabella Manni (ORCID: https://orcid.org/0000-0003-4823-0596)
- Giulia Piaggio (ORCID: https://orcid.org/0000-0003-2114-1892)
- Cristiana Ercolani (ORCID: https://orcid.org/0000-0003-0131-7766)
- Francesco Spallotta (ORCID: https://orcid.org/0000-0002-0466-6286)
Institutions
- Roma Tre University (IT)
- Institute of Molecular Biology and Pathology (IT)
- CTO Andrea Alesini (IT)
- Azienda Ospedaliera Sant'Andrea (IT)
- National Cancer Institute (MY)
- Cellular Therapeutics (United Kingdom) (GB)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1186/s13046-024-03189-3
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Associazione Italiana per la Ricerca sul Cancro